Korro Bio Reports 2024 Financial Results and Progress

Korro Bio, Inc. ( (KRRO) ) has released its Q4 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.

Korro Bio, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focusing on developing genetic medicines through RNA editing for rare and common diseases. The company recently announced its full-year 2024 financial results and provided updates on its business progress, highlighting significant advancements in its clinical programs and strategic collaborations.

In 2024, Korro Bio made notable strides by completing the dosing of the first two cohorts in its Phase 1/2a REWRITE clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). The company also received Orphan Drug Designation from the FDA for KRRO-110, which offers development incentives for treating rare diseases. Additionally, Korro strengthened its leadership team and continued its collaboration with Novo Nordisk, focusing on cardiometabolic diseases.

Financially, Korro Bio ended 2024 with $163.1 million in cash and marketable securities, ensuring a cash runway into the second half of 2026. The company reported $2.3 million in collaboration revenue, primarily from its partnership with Novo Nordisk. Research and development expenses increased to $63.6 million, reflecting ongoing investments in KRRO-110 and other pipeline candidates. General and administrative expenses also rose to $30.5 million due to expanded operations.

Looking ahead, Korro Bio plans to announce its second development candidate by the end of 2025 and aims to establish three clinical-stage programs by 2027. The company remains committed to advancing its RNA-editing platform and expanding its pipeline, with an interim readout of the REWRITE study expected in the second half of 2025.